Published in Ann Pharmacother on January 01, 2004
The dual role of p55 tumour necrosis factor-alpha receptor in Actinobacillus actinomycetemcomitans-induced experimental periodontitis: host protection and tissue destruction. Clin Exp Immunol (2007) 1.32
Association among C-reactive protein, Fatty liver disease, and cardiovascular risk. Dig Dis Sci (2007) 0.92
Relationship between echocardiographic findings and laboratory serum biomarkers in patients with and without low cardiac output. J Res Med Sci (2011) 0.87
New evidences for C-reactive protein (CRP) deposits in the arterial intima as a cardiovascular risk factor. Clin Interv Aging (2008) 0.83
Optimal lipid modification: the rationale for combination therapy. Vasc Health Risk Manag (2005) 0.82
Two Valid Measures of Self-rated Physical Activity and Capacity. Open Cardiovasc Med J (2012) 0.76
The relationship between serum levels of hs-CRP and coronary lesion severity. Clujul Med (2016) 0.76
High-sensitivity C-reactive protein and mean platelet volume in paediatric hypertension. Pediatr Nephrol (2010) 0.75
Development of a contemporary bleeding risk model for elderly warfarin recipients. Chest (2006) 3.54
Familial hypercholesterolemia: screening, diagnosis and management of pediatric and adult patients: clinical guidance from the National Lipid Association Expert Panel on Familial Hypercholesterolemia. J Clin Lipidol (2011) 1.58
Pseudohypertriglyceridemia: two cases of probable glycerol kinase deficiency. J Clin Lipidol (2012) 1.53
Monocyte tissue factor-dependent activation of coagulation in hypercholesterolemic mice and monkeys is inhibited by simvastatin. J Clin Invest (2012) 1.51
Vitamin D deficiency and supplementation and relation to cardiovascular health. Am J Cardiol (2011) 1.40
Accuracy and pharmacist perceptions of community-based automated blood pressure machines. J Am Pharm Assoc (2003) (2011) 1.38
Role of vitamin D in cardiovascular health. Am J Cardiol (2010) 1.26
Combined anticoagulant-antiplatelet use and major bleeding events in elderly atrial fibrillation patients. Stroke (2004) 1.23
Familial hypercholesterolemia: screening, diagnosis and management of pediatric and adult patients: clinical guidance from the National Lipid Association Expert Panel on Familial Hypercholesterolemia. J Clin Lipidol (2011) 1.22
Once-a-week rosuvastatin (2.5 to 20 mg) in patients with a previous statin intolerance. Am J Cardiol (2008) 1.16
Management of familial hypercholesterolemias in adult patients: recommendations from the National Lipid Association Expert Panel on Familial Hypercholesterolemia. J Clin Lipidol (2011) 1.09
Effectiveness and tolerability of every-other-day rosuvastatin dosing in patients with prior statin intolerance. Ann Pharmacother (2008) 1.04
Effects of once weekly rosuvastatin among patients with a prior statin intolerance. Am J Cardiol (2007) 0.96
Fibrates: what have we learned in the past 40 years? Pharmacotherapy (2007) 0.91
Does simvastatin cause more myotoxicity compared with other statins? Ann Pharmacother (2009) 0.90
Effect of low-density lipoprotein apheresis on inflammatory and noninflammatory high-density lipoprotein cholesterol. Am J Cardiol (2007) 0.89
Statin intolerance - an attempt at a unified definition. Position paper from an International Lipid Expert Panel. Expert Opin Drug Saf (2015) 0.89
Modified-policosanol does not reduce plasma lipoproteins in hyperlipidemic patients when used alone or in combination with statin therapy. Lipids (2011) 0.86
Important considerations for treatment with dietary supplement versus prescription niacin products. Postgrad Med (2011) 0.84
Optimal lipid modification: the rationale for combination therapy. Vasc Health Risk Manag (2005) 0.82
Association of HMG-CoA reductase inhibitors with neuropathy. Ann Pharmacother (2003) 0.81
The use of lipopheresis in the practice of clinical lipidology. J Clin Lipidol (2011) 0.81
Pseudohypertriglyceridemia--verifying the hypertriglyceridemic patient. J Clin Lipidol (2012) 0.80
A comparison of 25-hydroxyvitamin D serum levels among those with or without statin-associated myalgias. Atherosclerosis (2011) 0.80
Community pharmacy-based medication therapy management services: financial impact for patients. Pharm Pract (Granada) (2012) 0.78
Study of nonparticipation in an employee diabetes program. J Am Pharm Assoc (2003) (2012) 0.78
Eplerenone: a selective aldosterone receptor antagonist for patients with heart failure. Ann Pharmacother (2004) 0.78
Do ACE Inhibitors/Angiotensin II type 1 receptor antagonists reduce hospitalisations in older patients with heart failure? A propensity analysis. Drugs Aging (2007) 0.77
Re: Gómez-Gerique, et al. Effect of atorvastatin and bezafibrate on plasma levels of C-reactive protein in combined (mixed) hyperlipidemia. Atherosclerosis 2002;162:245-51. Atherosclerosis (2003) 0.77
Risk-stratified evaluation of amiodarone to prevent atrial fibrillation after cardiac surgery. Ann Thorac Surg (2006) 0.76
Apheresis therapy for retinal vasculitis. Arch Ophthalmol (2007) 0.75
Pulse pressure and risk of cardiovascular disease. JAMA (2003) 0.75
High-impact articles related to the pharmacotherapeutic management of systolic heart failure. Pharmacotherapy (2004) 0.75
The first case report of the treatment of transplant coronary artery disease with dextran sulfate adsorption lipid apheresis. Ther Apher Dial (2010) 0.75
P2Y₁₂ receptor inhibitors: integrating ticagrelor into the management of acute coronary syndrome. Ann Pharmacother (2011) 0.75
New treatment guidelines for unstable angina/non-ST-segment elevation myocardial infartion. Ann Pharmacother (2002) 0.75
Do statins have a role in the management of diastolic dysfunction? Am J Cardiovasc Drugs (2008) 0.75
The high-dose rosuvastatin once weekly study (the HD-ROWS). J Clin Lipidol (2011) 0.75